Viprostol (also known as CL115,347), a prostaglandin E2 congener that was studied as an antihypertensive agent. Viprostol has a potent and prolonged blood pressure lowering effect in many models of hypertension. In clinical studies, viprostol has been demonstrated to lower arterial blood pressure significantly in man following transdermal and/or intravenous administration. The antihypertensive action of viprostol has been suggested to be the result of peripheral vasodilatation. In addition, the drug participated in a clinical trial in normal subjects and in patients with Raynaud's phenomenon. It was found the optimal dosage was 1000 ug; the effect could last for 84 hours; higher dosage may be associated with a "steal" phenomenon.

Rosaprostol is an antiulcer drug. This compound acts on the mucosal barrier in the stomach, preventing a drop in pH. More specifically, rosaprostol exhibits gastric antisecretory activity and cytoprotective action. Importantly, it does not have the undesired side effects (such as diarrhea and uterine stimulation) of other prostanoids. Rosaprostol was found to antagonize gastric acid output induced by NSAID administration and to prevent and treat the digestive disorders that resulted from taking NSAIDs. Furthermore, symptoms in patients with gastritis disappeared after administration of rosaprostol, and the drug was well-tolerated. Positive effects of rosaprostol were also reported in patients with duodenal ulcer. Several stereoisomers of rosaprostol have been synthesized.

Ciprostene is a synthetic, chemically stable analog of prostacyclin (PGI2). In animal models, administration of ciprostene resulted in dose-dependent hypotension, tachycardia, and inhibition of ex vivo ADP-induced platelet aggregation. Ciprostene was evaluated in clinical trials in patients with peripheral vascular disease. It was found to reduce restenosis in patients with coronary artery disease undergoing therapeutic percutaneous transluminal coronary angioplasty.

Deprostil is prostaglandin E analog. The drug exhibits a prolonged inhibition of basal gastric acid secretion. Deprostil is the orally active anti-ulcer agent. It is a racemate with four possible optical isomers. Like deprostil the (nat)- and (epi)-isomers appear to be potentially useful therapeutic agents for the treatment of hypergastrlc acid secretion and peptic ulcers.

Naxaprostene (CG 4305) is a prostacyclin analogue, which causes concentration dependent inhibition of thrombocyte function. Naxaprostene is more selective for IP receptors and tends towards partial agonism. Naxaprostene prevented thrombotic arterial occlusion in rabbits.

LANPROSTON is an analog of prostaglandin F2 alpha. It is used as veterinary medicament.

Oxoprostol was developed as a gastric acid secretion inhibitor. Information about the further development of this drug is not available.

Piriprost (U-60, 257) is a structural analog of prostaglandin I2 (PGI2) with low IP receptor-mediated activity. It inhibits 5-LO (5-lipoxygenase). Piriprost inhibits the release of histamine and leukotrienes, implicating its role in inflammation and allergic responses. However, it was shown, that piriprost did not influence the airway responses after allergen in asthma. Nevertheless, even more, the drug was irritant to the respiratory tract than was placebo.